$34.13
+0.53 (+1.58%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ANRO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
12 interventional
Held by 8 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, Point72 Asset Management, L.P., Schonfeld Strategic Advisors LLC, MARSHALL WACE, LLP, TWO SIGMA INVESTMENTS, LP, +3 more) · FINRA short interest 7.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| ALTO-207 in Adults With Treatment-resistant Depression (TRD)NCT07553637Change in the MADRS total scoreRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: ALTO-207, Placebo | Treatment-resistant Depression (TRD) | 178 | Nov 2027 | ≤ 468 d | 2026-04-28 |
| Study of ALTO-300 in MDDNCT05922878To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS).Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: ALTO-300, Placebo | Major Depressive Disorder | 321 | Dec 2026 | ≤ 134 d | 2025-07-24 |
| ALTO-100 in Bipolar Disorder With Depression (BD-D)NCT06656416To assess efficacy of ALTO-100 versus placebo on depression symptoms in bipolar disorder in a pre-defined subgroup of participants as measured by the mean change from Day 1 to Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total scoreRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: ALTO-100, Placebo | Bipolar Disorder I or II With a Major Depressive Episode | 200 | Aug 2026 | ≤ 12 d | 2025-07-16 |
| Study of ALTO-101 in Patients With SchizophreniaNCT06502964Theta band activityRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: ALTO-101, Placebo · Device: ALTO-101 Transdermal Delivery System, Placebo Transdermal Delivery System | Schizophrenia, Cognitive Impairment | 82 | Feb 2026 | — | 2025-12-26 |
| PD, PK, and Safety of ALTO-203 in Patients With MDDNCT06391593Single Dose Period: To evaluate pharmacodynamic measures in patients with MDD after single doses of 25 μg ALTO-203, 75 μg ALTO-203, and placebo as measured by the alertness and mood components of the Bond-Lader Visual Analog Scale (BL-VAS).Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: ALTO-203 25 μg, ALTO-203 75 μg, Placebo | Major Depressive Disorder, Anhedonia | 69 | 2025-04-14actual | — | 2026-04-17 |
| Phase 2b Study of ALTO-100 in MDDNCT05712187To assess efficacy of ALTO-100 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change from Day 1 to Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: ALTO-100, Placebo | Major Depressive Disorder | 301 | 2024-09-05actual | — | 2025-09-08 |
| Leveraging EEG for Antidepressant Prediction With Duloxetine and BupropionNCT04388189Response rate on the 16-item patient-reported Quick Inventory of Depressive Symptoms (QIDS-SR) at the week 8 endpoint as a function of biomarker scoreRandomized · Open-label · Treatment | Phase 4 | Withdrawnsponsor's stated reason: No participants enrolled | Drug: Duloxetine, Bupropion | Major Depressive Disorder | 0 | 2023-05-30 | — | 2020-10-19 |
| Leveraging EEG for Antidepressant Prediction With Sertraline and EscitalopramNCT04388202Response rate on the 16-item patient-reported Quick Inventory of Depressive Symptoms (QIDS-SR) at the week 8 endpoint as a function of biomarker scoreRandomized · Open-label · Treatment | Phase 4 | Withdrawnsponsor's stated reason: No participants enrolled | Drug: Sertraline, Escitalopram | Major Depressive Disorder | 0 | 2023-05-30 | — | 2020-10-19 |
| ALTO-300 in DepressionNCT05118750To understand the relationship between baseline biology and clinical outcome to ALTO-300 using the Montgomery-Åsberg Depression Rating Scale (MADRS)Open-label · Treatment | Phase 2 | Completed | Drug: ALTO-300 oral (PO) tablet | Major Depressive Disorder | 91 | 2023-05-05actual | — | 2024-04-30 |
| ALTO-300 in Depression (ALTO-300-004)NCT05157945To understand the relationship between baseline biology and change in the Montgomery-Asberg Depression Rating Scale (MADRS) with ALTO-300Open-label · Treatment | Phase 2 | Completed | Drug: ALTO-300 PO Tablet | Major Depressive Disorder | 148 | 2023-04-26actual | — | 2024-04-26 |
| Pilot Decentralized TrialNCT05419869To understand the relationship between baseline biology and score change in the Montgomery-Asberg Depression Rating Scale (MADRS) with ALTO-100 from start of dosing to end of treatmentOpen-label · Treatment | Phase 2 | Completed | Drug: ALTO-100 PO Tablet | Major Depressive Disorder | 21 | 2023-01-13actual | — | 2024-01-18 |
| ALTO-100 in MDD and/or PTSDNCT05117632To understand the relationship between baseline biology and clinical outcome with ALTO-100 using the Montgomery-Åsberg Depression Rating Scale (MADRS)Open-label · Treatment | Phase 2 | Completed | Drug: ALTO-100 PO tablet | Major Depressive Disorder, Post Traumatic Stress Disorder | 245 | 2022-12-01actual | — | 2023-12-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19